[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Lichtman MA: Battling the hematological malignancies: the 200 years' war. Oncologist; 2008 Feb;13(2):126-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The delineation of the hematological malignancies began near the end of the first third of the 19th century with the recognition of the similarity among cases with lymph node tumors and an enlarged spleen (Hodgkin's disease).
  • In the first years of the 20th century the discovery of x-radiation permitted palliative orthovoltage radiation therapy of Hodgkin's disease.
  • Following World War II, legitimate drug therapy for the hematological malignancies was introduced: nitrogen mustard, adrenocorticotropic hormone and cortisone acetate, and anti-folic acid derivatives, initially aminopterin.
  • Today, about 14 classes of drugs (different mechanisms of action) and >50 individual agents are being used, with others under study.
  • Despite remarkable progress, including the ability to cure acute leukemia in about 70% of children, cure several genetic variants of acute myelogenous leukemia in younger adults, cure some cases of lymphoma in children and younger adults, and induce prolonged remission in many affected persons, the majority of patients face an uncertain outcome and shortened life.
  • The significant hurdles we must overcome include: the apparent infrequency of an exogenous cause that can be avoided, the exponential increase in incidence rates with age and the dramatic negative effect of aging on the results of treatment, the challenge of one trillion or more disseminated cancer cells among which are a smaller population of cancer stem cells, the profound genetic diversity of the hematological malignancies (apparently hundreds of unique genetic primary lesions), the redundant growth and survival pathways defining the cancer phenotype, the decreasing market for pharmaceutical companies as therapy becomes more specific (fewer target patients) and drug development costs become more expensive, and the significant negative long-term effects of current therapy on both children and adults.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia / drug therapy. Lymphoma / drug therapy. Multiple Myeloma / drug therapy
  • [MeSH-minor] Age Factors. Genetic Predisposition to Disease. History, 19th Century. History, 20th Century. History, 21st Century. Humans. Risk Factors. Time Factors. Treatment Outcome


2. Kim JK, Hahn JS, Kim GE, Yang WI: Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma. Yonsei Med J; 2005 Oct 31;46(5):703-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma.
  • Primary splenic lymphoma (PSL) is often defined as generalized lymphoma with splenic involvement as the dominant feature.
  • It is a rare disease that comprises approximately 1% of all malignant lymphomas.
  • We investigated three cases of non-Hodgkin's splenic lymphoma that had different clinical features on presentation.
  • The patients' survival times from diagnosis ranged from 59 to 143 months, without evidence of relapse after splenectomy and chemotherapy, with or without radiotherapy.
  • Further studies are needed to evaluate the impact that different treatment modalities without splenectomy have on patient survival.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Haematol. 2000 Mar;64(3):145-50 [10997879.001]
  • [Cites] Am J Clin Pathol. 1965 Apr;43:332-3 [14275850.001]
  • [Cites] Cancer. 1966 Apr;19(4):461-9 [5327041.001]
  • [Cites] Arch Intern Med. 1971 Feb;127(2):259-65 [5101153.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1606-19 [6548171.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Cancer. 1988 Oct 1;62(7):1433-8 [3416282.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2612-9 [2249201.001]
  • [Cites] Am J Hematol. 1991 Oct;38(2):95-100 [1951314.001]
  • [Cites] Surgery. 1992 Feb;111(2):224-7 [1736393.001]
  • [Cites] J Nucl Med. 1992 Jun;33(6):1183-5 [1597736.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):207-15 [8416717.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):286-93 [7926983.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] Clin Radiol. 1998 Feb;53(2):137-42 [9502091.001]
  • [Cites] Surg Gynecol Obstet. 1965 May;120:947-60 [14269844.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3731-3 [11054447.001]
  • (PMID = 16259071.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2810579
  •  go-up   go-down


3. Han SM, Teng CL, Hwang GY, Chou G, Tsai CA: Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture. J Chin Med Assoc; 2008 Apr;71(4):210-3
Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture.
  • Primary splenic lymphoma (PSL) is a rare disease with ambiguous definition, comprising less than 1% of non-Hodgkin's lymphoma.
  • We report the case of a 77-year-old man who presented with HLH initially.
  • Refusing diagnostic splenectomy, he received chemotherapy.
  • Spontaneous splenic rupture occurred after chemotherapy.
  • He received another 5 courses of chemotherapy with the R-CNOP regimen (rituximab, cyclophosphamide, mitoxantrone, vincristine, prednisolone).
  • Now he has no residual or relapsed disease.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / complications. Lymphoma, Large B-Cell, Diffuse / complications. Splenic Neoplasms / complications. Splenic Rupture / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436505.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Perfetto F, Tarquini R, Mancuso F, Di Lollo S, Tozzini S, Bellesi G, Laffi G: Hepato-splenic lymphoma: a rare entity mimicking acute hepatitis: a case report. World J Gastroenterol; 2003 Jun;9(6):1381-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepato-splenic lymphoma: a rare entity mimicking acute hepatitis: a case report.
  • We reported a case of non-Hodgkin's lymphoma where liver involvement was the predominant clinical manifestation.
  • Bone marrow biopsy showed an intracapillary infiltration of T-lymphocytes with no evidence of lipid storage disease.
  • Because of a progressive spleen enlargement, splenectomy was performed.
  • Histological examination showed lymphomatous intrasinuses invasion of the spleen.
  • Immunohistochemical investigation revealed the T phenotype of the neoplastic cells: CD45+, CD45RO+, CD3+, CD4-, CD8-, TIA1-.
  • The diagnosis of hepatosplenic T cell lymphoma was done.
  • The patient was treated with chemotherapy, which induced a complete remission.
  • In spite of autologous bone marrow transplantation, he died twenty months after the diagnosis.
  • Even in the absence of a mass lesion or lymphoadenopathy, hepatosplenic T-cell lymphoma should be considered in the differential diagnosis of a patient whose clinical course is atypical for acute hepatic dysfunction.
  • [MeSH-major] Hepatitis / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Humans. Male


5. Lee CK, Aeppli D, Nierengarten ME: The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):169-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience.
  • PURPOSE: To examine the long-term outcome of Stage I, II, and III patients treated with curative radiotherapy for Hodgkin's disease at the University of Minnesota Hospital, with particular focus on long-term treatment-related complications and the need for long-term surveillance after treatment.
  • Between 1970 and 1974, 35 high-risk patients (i.e., patients with large mediastinal mass, and/or hilar disease, and/or splenic involvement) and 40 low-risk patients were treated with standard field radiotherapy.
  • Salvage chemotherapy was given to 62 patients who recurred.
  • Long-term complications after treatment were assessed using standardized incidence ratios (SIR) and mortality ratios (SMR), with particular focus on cardiac complications and secondary malignancies.
  • Patients treated for Hodgkin's disease had about 7 times the risk of dying from cardiac problems (SMR = 7.2) and 10 times the risk of dying from a second malignancy (SMR = 10.3) compared to the general population.
  • In terms of absolute risk, Hodgkin's disease would cause seven additional deaths from secondary malignancies per year among 1000 patients and four additional deaths from cardiac problems.
  • CONCLUSION: Hodgkin's disease patients treated successfully with radiotherapy are at an increased risk for developing long-term treatment-related cardiac disease and/or second malignancies.
  • [MeSH-major] Cardiovascular Diseases / etiology. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Analysis of Variance. Cause of Death. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Recurrence. Salvage Therapy. Sex Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924987.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


6. Al-Ashgar HI, Khan MQ, Ghamdi AM, Bamehriz FY, Maghfoor I: Gastrosplenic fistula in Hodgkin's lymphoma treated successfully by laparoscopic surgery and chemotherapy. Saudi Med J; 2007 Dec;28(12):1898-900
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrosplenic fistula in Hodgkin's lymphoma treated successfully by laparoscopic surgery and chemotherapy.
  • A gastrosplenic fistula is a rare complication of a gastric or splenic lesion.
  • We report a case of Hodgkin's lymphoma nodular sclerosis involving the spleen that was complicated by spontaneous gastrosplenic fistula.
  • The fistula was closed laparoscopically, and the patient underwent partial gastrectomy and gastric wall repair, followed by successful chemotherapy.
  • If the fistula is caused by a malignant process, the surgical repair should be followed by definitive treatment with chemotherapy and radiotherapy.
  • [MeSH-major] Gastric Fistula / etiology. Gastric Fistula / therapy. Hodgkin Disease / complications. Splenic Diseases / etiology. Splenic Diseases / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Female. Humans. Laparoscopy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060225.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol; 2009 Nov 10;27(32):5390-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
  • PURPOSE: This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
  • PATIENTS AND METHODS: Patients had stage IIB, III, or IV disease or had stages I to IIA disease with bulky disease or other adverse features.
  • Radiotherapy was administered in both arms to sites of previous bulk (> 5 cm) and to splenic deposits, although this was omitted in the latter part of the trial for patients achieving complete remission (CR) in the ABVD arm.
  • A total of 520 patients were randomly assigned and were assessed for the primary outcome measure of progression-free survival (PFS).
  • Five hundred patients received protocol treatment, and radiotherapy was administered to 73% in the Stanford V arm and to 53% in the ABVD arm.
  • RESULTS: The overall response rates after completion of all treatment were 91% for Stanford V and 92% for ABVD.
  • During a median follow-up of 4.3 years, there was no evidence of a difference in projected 5-year PFS and overall survival (OS) rates (76% and 90%, respectively, for ABVD; 74% and 92%, respectively, for Stanford V).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Lung Diseases / chemically induced. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738111.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN64141244
  • [Grant] United Kingdom / Cancer Research UK / / C2422/A2858
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


8. Thorek DL, Tsao PY, Arora V, Zhou L, Eisenberg RA, Tsourkas A: In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS One; 2010;5(5):e10655
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: B cell depletion immunotherapy has been successfully employed to treat non-Hodgkin's lymphoma.
  • In recent years, increasing attention has been directed towards also using B-cell depletion therapy as a treatment option in autoimmune disorders.
  • METHODOLOGY/PRINCIPAL FINDINGS: Cellular imaging of the targeted population in vivo may provide significant insight towards effective therapy and a greater understanding of underlying disease mechanics.
  • Superparamagnetic iron oxide (SPIO) nanoparticles in concert with near infrared (NIR) fluorescent dyes were used to label and track primary C57BL/6 B cells.
  • Following antibody mediated B cell depletion (anti-CD79), NIR-only labeled cells were expeditiously cleared from the circulation and spleen.
  • Interestingly, B cells labeled with both SPIO and NIR were not depleted in the spleen.
  • CONCLUSIONS/SIGNIFICANCE: Whole body fluorescent tracking of B cells enabled noninvasive, longitudinal imaging of both the distribution and subsequent depletion of B lymphocytes in the spleen.
  • Quantification of depletion revealed a greater than 40% decrease in splenic fluorescent signal-to-background ratio in antibody treated versus control mice.
  • [MeSH-minor] Animals. Cells, Cultured. Fluorescence. Lymphocyte Depletion. Magnetic Resonance Imaging. Mice. Mice, Inbred C57BL. Organ Specificity. Spleen / immunology. Spleen / pathology. Staining and Labeling. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):410-4 [10748521.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Immunol Methods. 1994 Sep 30;175(1):79-87 [7930641.001]
  • [Cites] Int Immunol. 1997 Nov;9(11):1767-72 [9418137.001]
  • [Cites] Nat Med. 1998 Feb;4(2):245-7 [9461201.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Neurology. 1999 May 12;52(8):1701-4 [10331706.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3410-2; author reply 3412-3 [15525839.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):817-26 [15634903.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):4-13 [15616814.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):601-7 [15692974.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1096-102 [15657402.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] Acad Radiol. 2005 May;12 Suppl 1:S2-6 [16106536.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1407-13 [16258544.001]
  • [Cites] Mol Immunol. 2006 Feb;43(6):613-22 [15899518.001]
  • [Cites] Ann Biomed Eng. 2006 Jan;34(1):23-38 [16496086.001]
  • [Cites] Arthritis Rheum. 2006 May;54(5):1390-400 [16649186.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2793-806 [16947627.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):345-50 [17214580.001]
  • [Cites] Neuroimage. 2007;37 Suppl 1:S47-58 [17611126.001]
  • [Cites] Inflamm Res. 2007 Oct;56(10):391-401 [18026695.001]
  • [Cites] Immunol Invest. 2007;36(5-6):861-85 [18161533.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):676-88 [18272891.001]
  • [Cites] Clin Immunol. 2008 Mar;126(3):282-90 [18226586.001]
  • [Cites] Biomaterials. 2008 Sep;29(26):3583-90 [18533252.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):2961-72 [18713966.001]
  • [Cites] J Immunol. 2008 Oct 1;181(7):4770-9 [18802080.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1724-31 [18250115.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3765-72 [19029438.001]
  • [Cites] Mol Imaging Biol. 2009 May-Jun;11(3):178-87 [19034584.001]
  • [Cites] J Autoimmun. 2009 May-Jun;32(3-4):223-30 [19329279.001]
  • [Cites] AJR Am J Roentgenol. 2009 Aug;193(2):314-25 [19620426.001]
  • [Cites] J Immunol Methods. 2009 Oct 31;350(1-2):194-9 [19647745.001]
  • [Cites] Ann Neurol. 2009 Oct;66(4):460-71 [19847908.001]
  • [Cites] Curr Pharm Biotechnol. 2000 Jul;1(1):1-9 [11467356.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2029-33 [12209504.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2121-31 [12209517.001]
  • [Cites] Ann Rheum Dis. 2002 Oct;61(10):883-8 [12228157.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2673-7 [12384926.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9 [12640069.001]
  • [Cites] Muscle Nerve. 2003 May;27(5):611-5 [12707982.001]
  • [Cites] Science. 2003 Oct 24;302(5645):605-8 [14576425.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):971-80 [14999109.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2580-9 [15334472.001]
  • [Cites] Immunol Cell Biol. 1999 Dec;77(6):499-508 [10571670.001]
  • [Cites] Cytometry. 1990;11(2):231-8 [1690625.001]
  • (PMID = 20498725.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies
  • [Other-IDs] NLM/ PMC2871797
  •  go-up   go-down


9. Salmon JS, Thompson MA, Arildsen RC, Greer JP: Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations. Clin Lymphoma Myeloma; 2006 Jan;6(4):273-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations.
  • Primary hepatic non-Hodgkin's lymphoma (NHL) is a rare disease that presents unique diagnostic and therapeutic challenges.
  • Secondary liver involvement by lymphoma is common and can complicate treatment decisions.
  • A review of the published case reports and the few larger series suggests that primary hepatic NHL represents a heterogeneous mixture of disparate diseases rather than a single entity.
  • The clinical, laboratory, and radiographic characteristics are nonspecific, which means the diagnosis is often not suspected until histopathologic examination of liver tissue.
  • There appears to be a strong association between primary hepatic NHL and the hepatitis C virus.
  • Hepatosplenic T-cell lymphoma has attained its own status as a unique disease, whereas case reports suggest that the spectrum of hepatic lymphoma includes many histologies.
  • Involvement of the liver by lymphoma can compound the difficulty of pursuing aggressive chemotherapy in patients who have a life-threatening illness and impaired metabolism of the most effective drugs.
  • Therapy should be tailored to the individual clinical situation, with consideration of the underlying histology and degree of hepatic insufficiency.
  • [MeSH-major] Liver Neoplasms / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Hepatitis C / complications. Hepatitis C / pathology. Hepatitis C / therapy. Humans. Liver Failure / etiology. Liver Failure / pathology. Liver Failure / therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / secondary. Splenic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507204.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


10. Daskalogiannaki M, Prassopoulos P, Katrinakis G, Tritou I, Eliopoulos G, Gourtsoyiannis N: Splenic involvement in lymphomas. Evaluation on serial CT examinations. Acta Radiol; 2001 May;42(3):326-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic involvement in lymphomas. Evaluation on serial CT examinations.
  • PURPOSE: To prospectively evaluate changes in splenic volume (SV) on serial CT of patients with lymphoma and correlate them with other indicators of the disease process.
  • MATERIAL AND METHODS: SV was calculated in 290 abdominal CT examinations of 58 consecutive adults with lymphoma (42 non-Hodgkin's lymphoma, 16 Hodgkin's disease).
  • Each patient had one CT investigation before, 2 during chemotherapy and 2 post-chemotherapy.
  • The changes in SV were correlated with clinical, laboratory and other imaging indicators of the disease process.
  • Group A (n=20) presented no changes in SV, showed no splenic parenchymal abnormalities and had normal SV and serum lactic dehydrogenase (S-LDH).
  • Group B (n=25) presented a decrease in SV during treatment suggesting response to therapy.
  • Splenic parenchymal abnormalities (n=5) and other subdiaphragmatic sites of involvement (n=20) underwent remission during treatment.
  • Eighteen patients with high S-LDH at presentation showed normal values during therapy.
  • Group C (n=12) showed an increase in SV post-therapy associated with manifestations of disease recurrence.
  • The S-LDH levels were elevated in 10 patients at the same time.
  • CONCLUSION: Quantitatively assessed splenic size on CT may serve as an indicator of splenic involvement in the course of lymphomas.
  • [MeSH-major] Lymphoma / radiography. Spleen / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11350294.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


11. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P: Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol; 2000 Mar;18(5):972-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.
  • PURPOSE: This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy to bulky Hodgkin's disease sites.
  • PATIENTS AND METHODS: A two-stage design was implemented in a phase II study involving 47 patients with bulky mediastinal stage I/II or stage III/IV Hodgkin's disease.
  • Twelve weeks of the Stanford V chemotherapy regimen were given with consolidative radiotherapy (36 Gy) to lymph nodes >/= 5 cm and/or macroscopic splenic disease.
  • Treatment was administered in one of five institutions participating in the Eastern Cooperative Oncology Group.
  • RESULTS: With a median follow-up of 4.8 years, 45 patients are alive and 40 have been continuously disease-free.
  • There was one death from Hodgkin's disease and one death from an M5 acute leukemia.
  • Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantation.
  • CONCLUSION: Stanford V chemotherapy and consolidative radiotherapy to bulky disease is effective in bulky and advanced Hodgkin's disease in a multi-institutional setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Quality Control. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10694546.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636; etc
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


12. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • All patients were treated to 3600 cGy with a 400 cGy boost to the involved field.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • CONCLUSIONS: Careful clinical staging of early, asymptomatic HD patients treated with mantle, splenic, and EFRT may obviate the need for exploratory laparotomy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Win N, Tiwari D, Keevil VL, Needs M, Lakhani A: Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma. Hematology; 2007 Apr;12(2):159-62
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma.
  • The diagnosis of mixed-type autoimmune haemolytic anaemia (AIHA) is based on demonstrating the presence of "warm" IgG auto-antibody and "low titre" ( < 64 at 4 degrees C), "high thermal amplitude" (reacting at or >30 degrees C) "cold" IgM auto-antibody.
  • Mixed-type AIHA is uncommon.
  • Red cell agglutination on the peripheral blood film is a common finding in mixed-type AIHA and can lead, initially, to a mis-diagnosis of cold haemmagglutinin disease (CHAD).
  • Mixed-type AIHA is rare and can be idiopathic or secondary, often associated with systemic lupus erythematosus (SLE) and lymphoma.
  • In general, patients with mixed-type AIHA show a dramatic response to steroid therapy and frequently require few or no transfusions.
  • We report two unusual cases of mixed-type AIHA.
  • Case one was unusual as the patient developed AIHA while on steroid medication.
  • Case two, we believe, is the first reported case of splenic T cell angioimmunoblastic non-Hodgkins lymphoma (NHL) associated with mixed-type AIHA.
  • The patient failed to respond to steroids, intravenous immunoglobulin, chemotherapy and treatment with rituximab.
  • DAT tested with monospecific reagents, and thorough serological investigations is required to reach the diagnosis of mixed-type AIHA.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Anti-Inflammatory Agents / adverse effects. Lymphoma, T-Cell / complications. Paraneoplastic Syndromes / etiology. Prednisolone / adverse effects. Splenic Neoplasms / complications
  • [MeSH-minor] Aged. Antibodies, Anti-Idiotypic / blood. Antibodies, Anti-Idiotypic / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / blood. Autoantibodies / immunology. Combined Modality Therapy. Complement C3d / immunology. Coombs Test. Cryoglobulins / analysis. Cryoglobulins / immunology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Erythrocyte Transfusion. Fatal Outcome. Female. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunoglobulin M / blood. Immunoglobulin M / immunology. Immunoglobulins, Intravenous / therapeutic use. Immunosuppressive Agents / therapeutic use. Immunotherapy. Male. Osteoarthritis / drug therapy. Prednisone / administration & dosage. Rituximab. Splenectomy. Temperature. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454198.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Autoantibodies; 0 / Cryoglobulins; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80295-45-0 / Complement C3d; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


14. Chisesi T, Polistena P, Contu A, Coser P, Indrizzi L, Leoni P, Majolino I, Porcellini A, Salvagno L, Zambaldi G, Rizzoli V, Congiu AM, Santini G, Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG): Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients. Leuk Lymphoma; 2001 Mar;41(1-2):125-36
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
  • Here we report the results of a randomised multicenter phase III clinical trial which assesses the therapeutic efficacy and tolerability of a chemotherapy protocol CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) in adult and elderly patients with advanced intermediate and high-grade NHL.
  • Between October 1991 and October 1995, 139 patients, aged 55 to 79 years, with diffuse intermediate and high-grade lymphoma, were enrolled.
  • A considerable percentage of patients had clinically aggressive disease: 32.4% had systemic symptoms, 79% had stage III or IV disease, 33.8% had bone marrow involvement, 46% had splenic involvement and 42.5% had increased values of serum lactate dehydrogenate.
  • Complete remission was achieved in 70 of the 139 patients (51.9%) and PR in 12 (16.6%) with an overall response of 68.5%.
  • The overall response survival rate at 6 years was 39%, whereas DFS rate was 48.7% and PFS rate was 28.5%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Age Factors. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cyclophosphamide / toxicity. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / standards. Etoposide / toxicity. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / standards. Mitoxantrone / toxicity. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342364.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CEMP protocol
  •  go-up   go-down


15. Gardembas-Pain M, Mege M, Pabot du Chatelard P: [Asplenia in the Hodgkin's patient]. Presse Med; 2003 Sep 06;32(28 Suppl):S10-1
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asplenia in the Hodgkin's patient].
  • FEWER INDICATIONS AFTER SPLENECTOMY: Real therapeutic progress has been achieved over the last fifty years for patients with Hodgkin's disease known for their chronic immunodepression.
  • Since the advent of effective chemotherapy protocols such as ABVD, and more recently intensive chemotherapy completed as needed with an autograft, splenectomy is no longer performed for therapeutic purposes but may be indicated for its contribution to diagnosis.
  • STRATIFICATION OF RISK OF ASPLENISM: There remain however several questions concerning the infectious complications in these patients given chemotherapy and splenic radiotherapy.
  • One of the objectives of this work was to propose a stratification of risk of asplenism as a function of treatments administered, the level of initial immunodepression, and the age of the patient.
  • [MeSH-major] Hodgkin Disease / therapy. Splenectomy
  • [MeSH-minor] Antibiotic Prophylaxis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Immunosuppression. Prognosis. Radiotherapy / adverse effects. Radiotherapy Dosage. Recurrence. Risk Factors. Spleen / radiation effects. Spleen / transplantation. Time Factors. Transplantation, Autologous. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Asplenia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631638.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


16. Musteata VG, Corcimaru IT, Iacovleva IA, Musteata LZ, Suharschii IS, Antoci LT: Treatment options for primary splenic low-grade non-Hodgkin's lymphomas. Clin Lab Haematol; 2004 Dec;26(6):397-401
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for primary splenic low-grade non-Hodgkin's lymphomas.
  • The purpose of this comparative study was to evaluate the response of primary splenic low-grade non-Hodgkin's lymphomas (NHL) to chemotherapy, splenectomy, and chemotherapy combined with splenectomy in order to elaborate the optimum treatment modality.
  • A total of 104 patients (age range: 15-82 years) with primary low-grade B-cell NHL of the spleen were comprised by our study.
  • Stage IV disease was determined in 102 (98.1%) cases.
  • Regarding the treatment modality, splenectomy was performed in 14 patients, early splenectomy and single-agent chemotherapy in 15, early splenectomy and combined chemotherapy in 19, single-agent chemotherapy in 23, and combined chemotherapy in 33.
  • In the above-mentioned order, complete remission rate was following: none, 40.0, 31.6, 21.8, and 18.2%.
  • The median remission duration turned out to be longer (74.5 months) in the group of patients with complete remissions attained by means of splenectomy and combined chemotherapy.
  • Local relapses in the spleen developed in 19 (72.7%) patients treated with combined chemotherapy and in 9 (90.0%), who had undergone single-agent chemotherapy.
  • The 5-year overall survival was 54.4% after splenectomy, 39.4% after single-agent chemotherapy, and 37.1% after combined chemotherapy, being significantly higher (P <0.05) after splenectomy and single-agent chemotherapy (67.2%), and splenectomy followed by combined chemotherapy (64.7%).
  • Early splenectomy combined with chemotherapy is the optimum treatment option for primary low-grade NHL of the spleen because of the superiority in complete remission rate, remission duration, and in overall survival rate.
  • Splenectomy leads to somatic compensation of patients, makes impossible local relapsing in the spleen, prevents continuous dissemination from the primary tumor site, and mostly corrects cytopenias, creating better conditions for chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Splenectomy. Splenic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15595997.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ Jr, Paris KJ, Silverman CL, Yashar CM: Pediatric Hodgkin's disease. J Ky Med Assoc; 2004 Mar;102(3):104-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric Hodgkin's disease.
  • Twenty-five patients (78%) have nodular sclerosing type, 5 patients (16%) have mixed cellularity, and 2 patients (6%) have lymphocytic predominant type.
  • Eight patients (25%) were treated with radiation alone and 24 patients (75%) were treated with a combination of chemotherapy and radiation.
  • Of the radiation group, 5 patients were treated with mantle field; 2 patients with mantle, para-aortic node and splenic pedicles; and 1 patient with mini-mantle field.
  • The treatment was given with 4 or 6 mv photon, and the median dose was 36 Gray (range 32-40 Gy).
  • The median irradiation dose in the combination group was 25 Gy (range 21 Gy-36 Gy).
  • All patients in Stages I and II are alive without any evidence of disease at the last follow-up.
  • One patient with Stage III disease developed a second cancer (PNET: primitive neuroectodermal tumor) 111 months after combination treatment and has died.
  • One Stage IV patient has died with Hodgkin's disease 28 months after treatment with combination therapy.
  • All other patients are followed closely along with the primary physicians and consultants.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Mechlorethamine / therapeutic use. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vinblastine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15067795.001).
  • [ISSN] 0023-0294
  • [Journal-full-title] The Journal of the Kentucky Medical Association
  • [ISO-abbreviation] J Ky Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


18. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol; 2002 Feb 01;20(3):630-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.
  • PURPOSE: To provide more mature data on the efficacy and complications of a brief, dose-intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally extensive and advanced-stage Hodgkin's disease.
  • PATIENTS AND METHODS: One hundred forty-two patients with stage III or IV or locally extensive mediastinal stage I or II Hodgkin's disease received Stanford V chemotherapy for 12 weeks followed by 36-Gy RT to initial sites of bulky (> or =5 cm) or macroscopic splenic disease.
  • Late effects of treatment were recorded in follow-up.
  • RESULTS: With a median follow-up of 5.4 years, the 5-year FFP was 89% and the OS was 96%.
  • No patient progressed during treatment, and there were no treatment-related deaths.
  • FFP was significantly superior among patients with a prognostic score of 0 to 2 compared with those with a score of 3 and higher (94% v 75%, P <.0001).
  • To date, there have been 42 pregnancies after treatment.
  • CONCLUSION: These data confirm our preliminary report that Stanford V chemotherapy with RT to bulky disease sites is highly effective in locally extensive and advanced Hodgkin's disease.
  • It is most important to compare this approach with standard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy in the ongoing intergroup trial (E2496) to determine whether Stanford V with or without RT represents a therapeutic advance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Pregnancy. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2002 Feb 1;20(3):607-9 [11821436.001]
  • (PMID = 11821442.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2RO1 CA56060
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


19. De Sanctis V, Martelli M, Anticoli AP, Caronna R, Chirletti P, Giovannini M, Santarelli M, Enrici RM, Mandelli F: Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach. Anticancer Res; 2001 Nov-Dec;21(6A):4169-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
  • BACKGROUND: A brief course of chemotherapy followed by radiation therapy was considered the best treatment for localized high-grade Non-Hodgkin's Lymphoma (NHL).
  • The purpose of this study was to determine the efficacy and feasibility of a brief-course of anthracycline-based chemotherapy (CHOP) and consolidation radiation therapy (CRT) in a series of 57 consecutive patients with stage I-IE intermediate-high grade NHL.
  • Forty-four (77%) received a CRT and thirteen (23%) with primitive gastric and splenic NHL underwent radical surgery.
  • RESULTS: After a median follow-up of 84 months (range 4-128 months) the 5-year overall survival (OS), disease-free survival (DFS) and event-free survival (EFS) rates were 88%, 87.5% and 84%, respectively.
  • The 5-year OS, DFS and EFS was 100% in thirteen patients with primitive gastric or splenic NHL treated with a radical surgical approach followed by chemotherapy without CRT.
  • CONCLUSION: We confirm the efficacy and feasibility of a brief course of CHOP chemotherapy followed by CRT in localized I-IE intermediate-high grade NHL without adverse prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911313.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Forty-one patients underwent involved-field radiotherapy in conjunction with high-dose chemotherapy and bone marrow or peripheral stem cell transplantation.
  • Thirty-three patients received involved-field radiotherapy prior to stem cell transplantation directed at symptomatic and/or bulky sites; eight patients received involved-field radiotherapy after stem cell transplantation directed at sites of persistent disease.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • RESULTS: There were 124 deaths during the follow-up period, including 17% of the patients treated with involved-field radiotherapy and 44.2% of the patients receiving chemotherapy without involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • Five of the 41 patients treated with involved-field radiotherapy developed toxicity subsequent to treatment.
  • All but one of these patients had been treated with doses greater than 30 Gy.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Female. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic lymphoma: an elusive preoperative diagnosis.
  • Four patients underwent splenectomy for various clinical and radiological diagnoses and were found to have primary splenic lymphoma at surgery and histology.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • The first two patients had multiple nodules in the spleen measuring 0.1-0.5 cm while large cell lymphomas had large nodules (largest measuring 11 cm x 7 cm x 4 cm).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • One patient died, of causes not related to the disease process.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


22. Hull MC, Mendenhall NP, Colgan ME: Subdiaphragmatic Hodgkin's disease: the University of Florida experience. Int J Radiat Oncol Biol Phys; 2002 Jan 1;52(1):161-6
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subdiaphragmatic Hodgkin's disease: the University of Florida experience.
  • PURPOSE: To assess the long-term outcomes and late effects of patients with subdiaphragmatic Hodgkin's disease.
  • METHODS AND MATERIALS: Twenty-one patients with Stage I and II subdiaphragmatic Hodgkin's disease were treated with curative intent between February 1966 and February 1998 at the University of Florida.
  • Patient characteristics were as follows: mean age, 38.7 years (range, 3-75 years); 20 males and 1 female; 33% lymphocyte predominant, 43% nodular sclerosing, 14% mixed cellularity, 5% lymphocyte depletion, and 5% unclassified Hodgkin's disease.
  • Treatment included inverted Y irradiation (InY) (8 patients), total nodal irradiation (TNI) (7 patients), and combined modality irradiation and chemotherapy (CMT) (6 patients).
  • There were no deaths from Hodgkin's disease.
  • Treatment failures occurred in 1 of 8 patients after InY, 1 of 7 after TNI, and 1 of 6 after CMT.
  • Two of 3 recurrences were in patients with 3 or more sites of involvement and/or splenic involvement; 1 was in-field.
  • There were 5 second malignant neoplasms and 3 cardiac events, including 4 second malignant neoplasms and 2 cardiac events in the 9 patients > or =40 years old at diagnosis and 1 second malignant neoplasm and 1 cardiac event in the 12 patients <40 years old.
  • All 3 second solid malignancies in this study occurred 7-14 years after treatment in areas receiving 10-20 Gy.
  • CONCLUSIONS: Subdiaphragmatic Hodgkin's disease is an uncommon manifestation with excellent disease control achieved with InY, TNI, and CMT.
  • This subgroup of patients with Hodgkin's disease is predominantly male and older than subgroups with other presentations, which may predispose the group to a higher risk for serious adverse events after treatment.
  • We recommend InY with spleen for clinical Stages IA and nodular sclerosis or lymphocyte-predominant clinical Stage IIA, InY alone for pathologic Stages IA and IIA, and CMT for all Stage I/II patients with greater than three involved sites, B symptoms, bulky disease (>6 cm), central (para-aortic) presentation, or splenic involvement.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Diaphragm. Disease-Free Survival. Female. Florida. Follow-Up Studies. Humans. Inguinal Canal. Male. Mechlorethamine / administration & dosage. Middle Aged. Myocardial Infarction / etiology. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11777634.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; MOPP protocol
  •  go-up   go-down


23. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res; 2008 Dec;14(4):411-21
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
  • Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL).
  • Our aim was to examine clinical presentation, therapeutic and survival results of NLPHL patients in Hungary based on the data of two centres, and incidentally we analyzed the clinicopathological characteristics and differential diagnostic difficulties of this rare entity.
  • We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004.
  • Mean follow-up time was 82.7 (3-144) months of the total 536 HL patients.
  • Sixteen (3%) of the patients were diagnosed with NLPHL, 93% of them presented with early-stage disease.
  • None of the patients showed extranodal or splenic involvement or bulky disease.
  • One patient received chemotherapy alone, six received only involved field radiotherapy while six underwent combined modality treatment.
  • Overall response rate was 100% (93.75% complete).
  • Two NLPHL cases transformed to non-Hodgkin's lymphoma.
  • In contrast to the classical HL, the 10-year prognosticated overall survival rate was 100 vs. 82%, the event free survival was: 75% vs. 70%.
  • CONCLUSIONS: NLPHL is a rare disease, thus these are limited experiences with its diagnosis and treatment.
  • Since the disease has an excellent outcome, it is very important to prefer less toxic or local therapies to reach long term survival similar to that of the normal population.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Hungary. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 15;86(6):2312-20 [7662978.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Hematol Oncol. 2006 Sep;24(3):146-50 [16729353.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):184-9 [17591565.001]
  • [Cites] Acta Haematol. 1986;76(1):29-32 [3098024.001]
  • [Cites] Orv Hetil. 2002 Mar 31;143(13):651-61 [11975042.001]
  • [Cites] Blood. 1989 Jan;73(1):47-56 [2462943.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Sep 24;65(3):195-202 [12242134.001]
  • [Cites] Blood. 1996 Jul 15;88(2):657-66 [8695813.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):128-32 [16330953.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):787-804 [17908620.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:266-72 [17124071.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S45-56 [9926237.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):897-914 [17908627.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • (PMID = 18431694.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, Czuczman MS, Paplham P, Hahn T, McCarthy P: Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymphoma; 2004 Aug;45(8):1673-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
  • Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months.
  • We were able to successfully induce complete remission in a patient with alpha/beta HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath).
  • Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission.
  • These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Liver Neoplasms / therapy. Lymphocyte Transfusion. Lymphoma, T-Cell / therapy. Salvage Therapy. Splenic Neoplasms / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Humans. Male. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Remission Induction. Survival Rate. Time Factors. Tissue Donors. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370223.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Receptors, Antigen, T-Cell, alpha-beta; 3A189DH42V / alemtuzumab
  •  go-up   go-down


25. Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V: Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol; 2001 Jun 01;19(11):2905-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
  • PURPOSE: To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin's disease (HD).
  • PATIENTS AND METHODS: During 1988 to 1994, pathologically staged patients with stage I or II disease who were without risk factors (large mediastinal mass, extranodal lesions, massive splenic disease, elevated erythrocyte sedimentation rate, or three or more involved areas) were recruited from various centers.
  • All patients received 40 Gy total fractionated dose to the involved field areas but were randomly assigned to receive either 40 Gy (arm A) or 30 Gy (arm B) total fractionated dose for the clinically noninvolved EF.
  • No chemotherapy was given.
  • With a median follow-up of 86 months, 7-year relapse-free survival (RFS) rates were 78% (arm A) and 83% (arm B) (P =.093).
  • The most common causes of death (n = 27) were cardiorespiratory disease/pulmonary embolisms (seven), second malignancy (six), and HD (five).
  • The 30-Gy dose is adequate for clinically noninvolved areas.
  • Relapse patterns suggest that systemic therapy can reduce the 20% long-term relapse rate.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Dose Fractionation. Female. Humans. Male. Middle Aged. Patient Compliance. Prognosis. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387364.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Reiser M, Diehl V: Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer; 2002 Jun;38(9):1167-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment of follicular non-Hodgkin's lymphoma.
  • Most patients with follicular lymphoma are over 50 years of age and present with widespread disease at diagnosis.
  • Nodal involvement is very common, often accompanied by splenic and bone marrow disease.
  • The vast majority of patients with advanced stage follicular lymphoma are not cured using the current therapeutic options.
  • The rate of relapse is fairly consistent over time, even in patients who have achieved complete responses (CRs) to treatment.
  • Therapeutic options in follicular NHL include watchful waiting, oral alkylating agents, purine nucleoside analogues, combination chemotherapy, interferon and monoclonal antibodies.
  • The approval of rituximab, an unconjugated chimeric antibody against the CD20 antigen for the treatment of relapsed follicular B-cell NHL marked a milestone in the development of antibody treatment.
  • Various clinical trials combining monoclonal antibodies with conventional therapies are currently ongoing to determine whether these new biological agents will alter the natural history of follicular lymphoma.
  • [MeSH-major] Lymphoma, Follicular / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / methods. Hematopoietic Stem Cell Transplantation / methods. Humans. Interferons / therapeutic use. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12044501.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  • [Number-of-references] 44
  •  go-up   go-down


27. El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I: T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma; 2007 Sep;48(9):1764-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.
  • T-cell/histiocyte-rich B-cell lymphoma (TC/HRBCL) is a rare subtype of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with characteristic morphologic and immunophenotypic features, often misdiagnosed as Hodgkin's lymphoma and peripheral T-cell lymphoma.
  • Few and conflicting clinical data are available in the literature addressing optimal treatment, prognosis and outcome.
  • We retrospectively reviewed all patients diagnosed and managed at our institution between 1995 and 2004 diagnosed with T-cell-rich-B-cell lymphoma by WHO criteria.
  • Fifty-two percent of patients (32) had splenic involvement and thirty-seven patients (61%) presented with extranodal disease (22 >or= 2 sites).
  • All 59 newly diagnosed TC/HRBCL patients were treated with CHOP or R-CHOP combination chemotherapy +/- radiation therapy.
  • The overall response rate was 85% and nine patients progressed on therapy.
  • Fourteen patients relapsed with a median time of relapse of 6 months (range, 2 - 28).
  • At a median follow-up of 22 months (range 1 - 132); 32 patients (52%) are alive with no evidence of disease.
  • It has an aggressive course and poor outcome; with most of patients presenting with advanced disease stage together with high IPI score.
  • Treatment outcome seems to be similar to IPI matched DLBCL counterpart.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Salvage Therapy. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Sep;48(9):1670-1 [17786700.001]
  • (PMID = 17786712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


28. Malamitsi J, Kosmidis H, Valotassiou B, Bonou I, Andreou J: Negative gallium-67 citrate and positive positron emission tomography/computed tomography spleen scans, in Hodgkin's stage IV lymphoma. Hell J Nucl Med; 2007 May-Aug;10(2):116-8
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative gallium-67 citrate and positive positron emission tomography/computed tomography spleen scans, in Hodgkin's stage IV lymphoma.
  • An 18-year-old male patient with Hodgkin's lymphoma stage IVB (HL-IVB), is presented.
  • On a follow-up examination a splenic ultrasound scan showed the presence of multiple intense nodules.
  • The gallium-67 citrate, single photon emission tomography scan was negative, while positron emission tomography/computerized tomography (PET/CT) scan with fluoro-18-fluordeoxyglucose was strongly positive.
  • Massive infiltration of the spleen by HL-IVB tissue was confirmed by pathology after splenectomy.
  • Two successive PET/CT studies for follow-up purposes three and twelve months after completion of chemotherapy, were normal.
  • [MeSH-major] Citrates. Gallium. Gallium Radioisotopes. Hodgkin Disease / diagnosis. Hodgkin Disease / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Metastasis. Neoplasm Staging. Recurrence. Spleen / pathology. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684589.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Citrates; 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


29. Drini M, Prichard PJ, Brown GJ, Macrae FA: Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med J Aust; 2008 Oct 20;189(8):464-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
  • Tumour necrosis factor inhibitors have revolutionised the management of Crohn's disease, but reports of a possible association between concomitant infliximab and immunomodulator therapy and hepatosplenic T-cell lymphoma (a rare form of aggressive non-Hodgkin's lymphoma) have emerged.
  • We describe the first case in Australia of hepatosplenic T-cell lymphoma in a patient who had been treated with infliximab and immunomodulators for Crohn's disease.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Liver Neoplasms / chemically induced. Lymphoma, T-Cell / chemically induced. Splenic Neoplasms / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Crohn Disease / drug therapy. Fatal Outcome. Humans. Immunologic Factors / adverse effects. Immunologic Factors / therapeutic use. Infliximab. Male

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med J Aust. 2009 Mar 16;190(6):341-2 [19296822.001]
  • (PMID = 18928444.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunologic Factors; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


30. Chajari M, Lacroix J, Peny AM, Chesnay E, Batalla A, Henry-Amar M, Delcambre C, Génot JY, Fruchard C, Bardet S: Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography? Eur J Nucl Med Mol Imaging; 2002 Mar;29(3):380-7
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
  • The usefulness and complementarity of gallium (67Ga) scintigraphy and computed tomography (CT) in the management of patients with lymphoma have been extensively demonstrated.
  • As fusion imaging techniques between single-photon emission tomography (SPET) and CT have been developed recently, we investigated whether use of CT/67Ga SPET fusion imaging could help in the interpretation of 67Ga scintigraphy.
  • From November 1999 to May 2001, 52 consecutive fusion studies were performed in 38 patients [22 patients with Hodgkin's disease (HD) and 16 patients with non-Hodgkin's lymphoma (NHL)] as part of pre-treatment staging (n=13), treatment evaluation (n=20) or evaluation of suspected recurrence (n=19).
  • Image fusion was considered to be of benefit in 12/52 (23%) studies which were performed for initial staging (n=4), treatment evaluation (n=4) or evaluation of suspected recurrence (n=4).
  • In these cases, image fusion allowed either confirmation and/or localisation of pathological gallium uptake (n=10) or detection of lesions not visible on CT scan (n=2).
  • In the abdomen and pelvis, fusion helped to differentiate physiological bowel elimination from abnormal uptake, and assisted in precisely locating uptake in neighbouring viscera of the left hypochondrium, including the spleen, left liver lobe, coeliac area, stomach wall and even the splenic flexure.
  • Clinical management was altered by fusion imaging in one patient (chemotherapy was given instead of radiotherapy) and was potentially affected in three other patients (in that, in conjunction with other factors, the results of fusion imaging had an influence on the decision regarding use of irradiation and especially the treatment volume).
  • In conclusion, CT/67Ga SPET fusion imaging allowed precise localisation of gallium uptake and correct attribution to the involved viscera, thereby altering the diagnosis in 20%-25% of studies in comparison with CT and 67Ga SPET analyses alone.
  • CT/67Ga SPET fusion therefore appears valuable in facilitating the interpretation of 67Ga scintigraphy and we recommend its use in patients with lymphoma when CT and 67Ga scintigraphy are planned.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002715.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


31. Lehmberg K, Steinhausen B, Janka G: From neonates to adolescents--the diagnostic significance of pitted erythrocytes in hyposplenic and asplenic children. Klin Padiatr; 2007 Nov-Dec;219(6):339-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Splenic function may be reduced or absent in a range of medical conditions in childhood, most prominently in homozygous sickle cell disease, celiac disease, or after total or partial splenectomy.
  • In neonates and patients with malignant disease, transient hyposplenia has been reported as well.
  • A simple method with reliable reference values is required to determine a patient's splenic function and thereby assess the risk of systemic infection.
  • This included splenectomized individuals, patients at risk for hyposplenia (homozygous sickle cell anemia (HbSS), leukemia, nephroblastoma and Hodgkin's disease after irradiation, patients after stem cell transplantation (SCT)), term and preterm neonates, and 90 controls (0-20 years of age, no neonates).
  • Scores did not exceed 2% in patients after SCT, irradiation, or during chemotherapy for leukaemia.
  • CONCLUSION: Serial measurement of pitE can be used to accurately and reliably assess splenic function in children.
  • [MeSH-major] Anemia, Sickle Cell / diagnosis. Erythrocytes, Abnormal. Spleen / physiology. Splenectomy

  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050044.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Foti R, Fazio P, Lizzio G, Leonardi R: [Angioedema: first manifestation of non-Hodgkin's lymphoma]. Ann Ital Med Int; 2002 Jul-Sep;17(3):185-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioedema: first manifestation of non-Hodgkin's lymphoma].
  • [Transliterated title] Angioedema: prima manifestazione di linfoma non Hodgkin.
  • Hereditary angioedema is a genetic disease transmitted with an autosomal dominant mechanism.
  • Acquired angioedema usually occurs after the second decade of life and is often related to an underlying disease.
  • In a 48-year-old male patient a diagnosis of a non-Hodgkin lymphoma was made after two episodes of angioedema.
  • Abdominal ultrasonography and computed tomography showed two solid splenic masses infiltrating the greater curvature of the stomach and a 2 cm aortic lymph node.
  • A diagnosis of anaplastic large-cells lymphoma CD30+, anaplastic lymphoma kinase negative was made.
  • The disappearance of the neoplastic gastric infiltration and the decrease in size of the aortic lymph node and splenic mass were achieved after chemotherapy.
  • An adult onset not associated with a family history of angioedema should lead the physician to suspect the presence of a major disease.
  • [MeSH-major] Angioedema / etiology. Autoimmune Diseases / etiology. Complement C1 Inactivator Proteins / deficiency. Complement C1 Inactivator Proteins / immunology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Proteins / analysis. Prednisone / administration & dosage. Spleen / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Ital Med Int. 2002 Jul-Sep;17(3):143-5 [12402660.001]
  • (PMID = 12402667.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Complement C1 Inactivator Proteins; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


33. Elmahy H, Hawley I, Beard J: Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination. Int J Lab Hematol; 2007 Dec;29(6):461-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination.
  • The simultaneous occurrence of Hodgkin lymphoma with a variety of B-cell Non-Hodgkin lymphomas (composite lymphoma) has been described.
  • We report the first case of composite Hodgkin lymphoma and splenic marginal zone lymphoma occurring simultaneously in the same lymph node of a 64-year-old man who presented with cervical and axillary lymphadenopathy and massive splenomegaly.
  • However, cervical lymph node biopsy showed classic Hodgkin lymphoma.
  • His splenomegaly showed only a partial response to six cycles of ABVD chemotherapy so he underwent splenectomy with biopsy of remaining nodes.
  • Histology of the spleen and nodes showed splenic marginal zone lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bleomycin / administration & dosage. Bone Marrow Cells / pathology. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymph Nodes / pathology. Lymphocytes / pathology. Lymphocytosis / pathology. Lymphocytosis / therapy. Male. Middle Aged. Splenectomy. Splenomegaly / pathology. Splenomegaly / therapy. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988302.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


34. Liebman H: Other immune thrombocytopenias. Semin Hematol; 2007 Oct;44(4 Suppl 5):S24-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immune thrombocytopenic purpura (ITP) can be classified as primary (known also as idiopathic thrombocytopenic purpura) or as secondary to an underlying condition such as a malignant or nonmalignant disorder.
  • Commonly occurring conditions associated with secondary ITP include lymphoproliferative disorders (chronic lymphocytic leukemia [CLL], Hodgkin's disease and non-Hodgkin's lymphomas), autoimmune collagen vascular diseases (systemic lupus erythematosus [SLE], thyroid disease, antiphospholipid syndrome [APS]), and chronic infections (human immunodeficiency virus [HIV], Helicobacter pylori, hepatitis C virus [HCV]).
  • The mechanism of platelet destruction in thrombocytopenias associated with lymphoproliferative disorders and collagen vascular diseases is identical to the autoimmune mechanism seen in primary ITP.
  • Drug-induced thrombocytopenias are uncommon and generally resolve quickly upon drug discontinuation, but are often attributed to other causes.
  • Platelet destruction in infection-associated ITP occurs via various mechanisms including accelerated platelet clearance due to immune complex disease as seen in HIV infection or cross-reactivity of anti-platelet glycoprotein antibodies and viral antigens in HIV, HCV, and H pylori infections (antigenic mimicry).
  • In patients with HCV-related cirrhotic liver disease, splenic sequestration secondary to portal hypertension and decreased production of thrombopoietin may further contribute to development of thrombocytopenia.
  • The current treatment paradigm for secondary ITP varies according to the underlying condition.
  • Standard treatments for primary ITP (corticosteroids, IVIG, anti-D, splenectomy) are often successful in secondary ITP.
  • In cases of ITP with H pylori and HCV infection, treatment should focus on the underlying disorder.
  • [MeSH-major] Blood Platelets / immunology. Thrombocytopenia / diagnosis. Thrombocytopenia / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / immunology. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / drug therapy. Antiphospholipid Syndrome / immunology. Diagnosis, Differential. Female. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / immunology. Hepatitis C / complications. Hepatitis C / drug therapy. Hepatitis C / immunology. Humans. Leukemia / complications. Leukemia / drug therapy. Leukemia / immunology. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Lupus Erythematosus, Systemic / immunology. Lymphoma / complications. Lymphoma / immunology. Lymphoma / therapy. Male. Platelet Count. Thyroid Diseases / complications. Thyroid Diseases / immunology. Thyroid Diseases / therapy

  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096469.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 152
  •  go-up   go-down


35. Biasoli I, Morais JC, Soares de Jesus P, Pulcheri W, Nucci M, Spector N: Application of an adapted international prognostic index for aggressive non-Hodgkin's lymphomas: good discrimination and lower survival rates in Rio de Janeiro, Brazil. Oncol Rep; 2001 Mar-Apr;8(2):441-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of an adapted international prognostic index for aggressive non-Hodgkin's lymphomas: good discrimination and lower survival rates in Rio de Janeiro, Brazil.
  • Institutions that treat patients with lymphoma must know their local therapy results and adapt their treatment strategies accordingly.
  • We also collapsed the four categories of the IPI into two categories, and applied this adapted IPI to patients with aggressive non-Hodgkin's lymphoma treated in a public university hospital.
  • Among the 72 patients treated with combination chemotherapy regimens containing doxorubicin, the following outcomes were observed for low and high risk groups, respectively: complete remission rates were 62% and 45% (p=0.2), overall survival rates were 48% and 14% (p=0.0098) and failure-free survival rates were 44% and 17% (p=0.03).
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Bone Marrow / pathology. Brazil. Child. Disease-Free Survival. Female. Hospitals, Public. Hospitals, University. Humans. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Liver Neoplasms / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Splenic Neoplasms / mortality. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Survival Rate. Urban Population

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11182071.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


36. Seib CD, Rocha FG, Hwang DG, Shoji BT: Gastrosplenic fistula from Hodgkin's lymphoma. J Clin Oncol; 2009 Jul 10;27(20):e15-7
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrosplenic fistula from Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fistula / diagnosis. Gastric Fistula / diagnosis. Hodgkin Disease / drug therapy. Splenic Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433680.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement